MINNEAPOLIS, Nov 28, 2011 (GlobeNewswire via COMTEX) --Urologix, Inc. (Nasdaq:ULGX) is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customers two proven technologies to treat the widest range of patients suffering from enlarged prostate in the comfort of their office setting, Cooled ThermoTherapy(TM) (CTT) and Prostiva(R) RF Therapy. Today, the Company announced it will present at the...
MINNEAPOLIS, Nov 10, 2011 (GlobeNewswire via COMTEX) --
Urologix, Inc. (Nasdaq:ULGX), is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customers two proven technologies to treat the widest range of patients suffering from enlarged prostate in the comfort of their office setting, Cooled ThermoTherapy(TM) (CTT) and Prostiva(R) RF Therapy. Today, the Company announced it will present at...
-- Addition of Prostiva RF Therapy expands customer base and addressable
patient population
-- $3.1 million in total revenue, 8% sequential revenue growth
-- Sales force expanded with addition of Prostiva sales representatives
MINNEAPOLIS, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Urologix(R), Inc. (Nasdaq:ULGX), is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customer...
MINNEAPOLIS, Nov 02, 2011 (BUSINESS WIRE) -- Urologix(R), Inc. (Nasdaq: ULGX) will host a conference call to present fiscal year 2012 first quarter results on Monday, November 7, 2011 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-800-901-5226 and enter the Participant Passcode 27237799 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at http://www.urologix.com. Stryker W...
-- Urologix becomes the leading provider of in-office solutions for the
early and effective treatment of obstructive urinary conditions due to
benign prostatic hyperplasia (BPH)
-- Diversifies revenue base with potential for significant operating
leverage
-- Provides a strategic growth platform while expanding sales coverage and
customer base
-- Combined revenues in fiscal 2012 expected to be in the range of $18 to
$20 million
MINNEAPOLIS,...
-- Revenue of $2.9 million, for the fourth quarter and $12.6 million for
fiscal year 2011.
-- A net loss of $1.3 million, or $0.09 per diluted share in the fourth
quarter and $3.7 million or $0.26 per diluted share for fiscal year
2011.
-- New Vice President of Sales and Marketing joins Urologix.
MINNEAPOLIS, Aug. 23, 2011 (GLOBE NEWSWIRE) -- Urologix(R), Inc. (Nasdaq:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ...
MINNEAPOLIS, Aug 17, 2011 (BUSINESS WIRE) -- Urologix(R), Inc. (NASDAQ:ULGX) will host a conference call to present fiscal year 2011 and fourth quarter results on Tuesday, August 23, 2011 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-800-435-1398 and enter the Participant Passcode 73391076 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at http://www.urologix.com. Stryk...
MINNEAPOLIS, Jun 30, 2011 (GlobeNewswire via COMTEX) --
Urologix, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH) announced today that it received a letter, dated June 29, 2011, from The Nasdaq Stock Market notifying Urologix that it has regained compliance with the $1.00 per share minimum bid price requirement for continued listin...
MINNEAPOLIS, Jun 16, 2011 (GlobeNewswire via COMTEX) --
Urologix(R), Inc. (Nasdaq:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy(TM) (CTT) technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the appointment of Lisa Ackermann as its Vice President, Sales and Marketing effective June 16, 2011. Ms. Ackermann will report to the Compan...
MINNEAPOLIS, Apr 26, 2011 (GlobeNewswire via COMTEX) --Urologix(R), Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the third quarter of its fiscal year 2011 that ended March 31, 2011.
Fiscal year 2011 third-quarter revenue was $3.0 million, down 10 percent from the $3.3 million reported in ...
-- Only 11% of patients required BPH drugs at 5 years post treatment
-- 90% freedom from secondary procedures though 5 years
MINNEAPOLIS, April 26, 2011 (GLOBE NEWSWIRE) -- Urologix(R), Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today announced publication of long-term data in the May issue of The Journal of Uro...
MINNEAPOLIS, Apr 20, 2011 (BUSINESS WIRE) -- Urologix(R), Inc. (Nasdaq:ULGX) will host a conference call to present fiscal 2011 third quarter results on Tuesday, April 26, 2011 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-783-2144 and enter the Participant Passcode 98372867 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Stryker Warren, Jr., Ch...
MINNEAPOLIS, Feb 16, 2011 (GlobeNewswire via COMTEX) --Urologix, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, ...
MINNEAPOLIS, Jan 25, 2011 (GlobeNewswire via COMTEX) --
Urologix(R), Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the second quarter of its fiscal year 2011 that ended December 31, 2010.
Fiscal year 2011 second-quarter revenue was $3.3 million, down 1 percent from the $3.4 million report...
MINNEAPOLIS, Jan 19, 2011 (BUSINESS WIRE) --Urologix(R), Inc. (Nasdaq:ULGX) will host a conference call to
present fiscal 2011 second quarter results on Tuesday, January 25, 2011
at 4:00 p.m. CT, following the Company's post-market press release on
the same day. On the day of the call, please dial 1-866-362-4831 and
enter the Participant Passcode 10194653 at least 10 minutes prior to the
call. The conference call will be broadcast live over the Internet at...
MINNEAPOLIS, Jan 6, 2011 (GlobeNewswire via COMTEX) --Urologix(R), Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy(TM) (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today announced that it will be presenting at the semi-annual Sidoti Micro-Cap Conference on Monday, January 10, 2011, at 11:20 a.m. Eastern Time. The event is being held at The Grand Hyatt Hotel, Park Avenue at Grand C...
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Urologix, Inc. has a press release. Just enter your e-mail address and click Submit.
